Use of the monoclonal antibody MOC-31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology

Cancer Cytopathology

Volumn 119, Issue 4, 2011, Pages 272-278

  Kundu, Uma R ^a   Krishnamurthy, Savitri ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; Effusion cytology; MOC 31; Reactive mesothelial cells mesothelioma

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MOC 31; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; TUMOR MARKER;

ADENOCARCINOMA; ANTIBODY DETECTION; APPENDIX ADENOCARCINOMA; ARTICLE; ASCITES; BILIARY TRACT ADENOCARCINOMA; BREAST ADENOCARCINOMA; CANCER OF UNKNOWN PRIMARY SITE; CELL STRUCTURE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOLOGY; CYTOPATHOLOGY; DISEASE MARKER; EFFUSION; ENDOMETRIUM CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; MESOTHELIOMA; METASTASIS POTENTIAL; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PERITONEAL FLUID; PLEURA FLUID; PREDICTIVE VALUE; PRIORITY JOURNAL; RECTUM CARCINOMA; SARCOMA; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; THYROID CARCINOMA; CELL MEMBRANE; DIFFERENTIAL DIAGNOSIS; ENZYME IMMUNOASSAY; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; CELL MEMBRANE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOENZYME TECHNIQUES; MESOTHELIOMA; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054030458     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20164     Document Type: Article

References (22)

1. Morgan RL, De Young BR, McGaughy VR, Niemann TH. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer. 1999;87:390-394.
2. Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer. 2001;93:68-72.
3. Dejmek A, Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol. 2005;32:160-166.
4. Saleh HA, El-Fakharany M, Makki H, Kadhim A, Masood S. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis. Diagn Cytopathol. 2009;37:324-332.
5. Butnor KJ. My approach to the diagnosis of mesothelial lesions. J Clin Pathol. 2006;59:564-574.
6. Ruitenbeek T, Gouw AS, Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med. 1994;118:265-269.
7. Ordonez N. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006;19:34-48.
8. Ordonez N. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesotheliomaA review and update. Hum Pathol. 2007;38:1-16.
9. Kim J, Kim G, Choi YD, et al. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks. Diagn Cytopathol. 2009;37:258-261.
10. Sosolik RC, McGaughy VR, De Young BR. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol. 1997;10:716-719.
11. Ordonez N. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol. 2006;13:16-25.
12. Chen LM, Lazcano O, Katzmann JA, Kimlinger TK, Li CY. The role of conventional cytology, immunocytochemistry, and flow cytometric DNA ploidy in the evaluation of body cavity fluids: a prospective study of 52 patients. Am J Clin Pathol. 1998;109:712-721.
13. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol. 1997;17:115-120.
14. Ueda J, Iwata T, Ono M, Takahashi M. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion. Diagn Cytopathol. 2006;34:6-10.
15. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol. 2005;32:151-155.
16. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytologyArch Pathol Lab Med. 2008;132:23-28.
17. Athanassiadou P, Gonidi M, Liossi A, et al. Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: an immunocytochemical study. Pathol Oncol Res. 2000;6:100-103.
18. Su XY, Li GD, Liu WP, Xie B, Jiang YH. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry [published online ahead of print September 10, 2010]. Diagn Cytopathol.
19. Hecht JL, Pinkus JL, Pinkus GS. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations. Cancer (Cancer Cytopathol). 2006; 108:56-59.
20. Sun Y, Wu GP, Fang CQ, Liu SL. Diagnostic utility of MOC-31, HBME-1 and MOC-31 mRNA in distinguishing between carcinoma cells and reactive mesothelial cells in pleural effusions. Acta Cytol. 2009;53:619-624.
21. Delahaye M, Hoogsteden HC, van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol. 1991;165: 137-143.
22. Gong Y, Sun X, Michael CW, Attal S, Williamson BA, Bedrossian CW. Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block. Diagn Cytopathol. 2002;28:1-5.